Neurogene Inc. - Common Stock (NGNE)

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.

The company is now scrapping a high dose of its Rett syndrome drug after a patient experienced a serious side effect.

Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks.

Neurogene tested its gene therapy in female patients with Rett syndrome.

Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing improved safety and efficacy.